2-(Thienothiazolylimino)-1,3-thiazolidin-4-ones inhibit cell division cycle 25 A phosphatase

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Oncology

Background:

• Cell division cycle dual phosphatases (CDC25) are critical regulators of cell cycle progression.
• Over-expression of CDC25 enzymes (CDC25A, B, and C) is implicated in various cancers.
• Thiazolidinone derivatives are known for their diverse biological activities, including anti-proliferative effects.

Purpose of the Study:

• To synthesize and evaluate novel 2-(thienothiazolylimino)-1,3-thiazolidin-4-one derivatives as inhibitors of CDC25 phosphatases.
• To investigate the inhibitory potential of these compounds against cancer-related targets.

Main Methods:

• Synthesis of novel 4-thiazolidinone derivatives.
• In vitro enzymatic assays to determine CDC25 phosphatase inhibition (IC50 values).
• Cell-based assays using MCF7 and MDA-MB-231 cancer cell lines to assess anti-proliferative effects.

Main Results:

• Compound 6 demonstrated significant inhibition of CDC25A phosphatase with an IC50 of 6.2±1.0μM.
• The binding of compound 6 to CDC25A was determined to be reversible.
• Compound 6 induced cell growth arrest in both MCF7 and MDA-MB-231 cancer cell lines in vitro.

Conclusions:

• Novel 4-thiazolidinone derivatives, specifically compound 6, show potential as inhibitors of CDC25A phosphatase.
• These findings represent the first characterization of such derivatives as CDC25 inhibitors.
• Compound 6 warrants further investigation as a potential therapeutic agent for cancers associated with CDC25 over-expression.